Search

everythinglearnresearchcommunity

for

Search:↓

The post discusses the positive results of an 11-month treatment with Finasteride and an 8-month treatment with Minoxidil foam for hair loss. The most noticeable improvement was seen around the 5-6 month mark.

User experienced significant hair improvement after 9 months using topical fin/min spray. Noticed positive changes around 3-month mark and chose topical treatment due to fewer side effects.

Long term Finasteride users and whether or not they have noticed improvements after two years of use, with other treatments such as Minoxidil and dermarolling also discussed. Some replies suggest that improvement is possible even beyond the two year mark while others caution against believing studies backed by the Post-Finasteride Foundation.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.

Treatments for hair loss, with the user considering Pyrilutamide and RU58841 as options. It is noted that although Pyrilutamide has been studied more and is allegedly more effective, there are doubts about its authenticity in the market. KX-826 is suggested as an alternative as it has a stronger effect than RU58841 and there is scientific research on it.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.

The potential effectiveness of homemade topical spironolactone in treating hair loss, with studies suggesting it is more effective than finasteride and even minoxidil when used as monotherapy. The conversation also mentions that other anti-androgens are being developed which may soon hit the market.

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

A 28-year-old is experiencing worsening hair loss despite using finasteride, minoxidil, microneedling, Nizoral, Selsun Blue, and supplements. Suggestions include trying Dutasteride or considering a hair transplant if no improvement is seen by the two-year mark.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The user shared a 15-month hair loss treatment update using Dutasteride (0.5mg/day), Minoxidil (5% foam twice daily), Nizoral (1% every 3 days), and a 1.5mm derma roller (twice a month), along with a multivitamin, exercise, low sugar diet, hydration, and consistent sleep. They started seeing results after 6-9 months, with significant improvement at the 1-year mark, and apply Minoxidil the day after derma rolling.

A user's positive early results after 2.5 months of using a topical finasteride/minoxidil spray and Nizoral twice a week for hair loss. The user, who started losing hair six years ago at age 22, is asked to share further progress at the six-month mark.

The user switched from finasteride to dutasteride for hair loss treatment, but experienced increased libido, itchy scalp, and accelerated hair loss. Another user suggested that genetic variations might cause dutasteride to be less effective and recommended checking for specific genetic markers.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

A user's 15-month experience with oral finasteride, minoxidil, zinc and vitamin C, caffeine, and microneedling as treatments for hair loss, which has yielded impressive results. Suggestions were made to stack a topical DHT blocker with the finasteride or increase the microneedling regimen, and it was suggested to re-evaluate at the two year mark.

User's 2-month hair loss treatment includes Dut 0.5mg, oral min 2.5mg, Dut+PRP mesotherapy, microneedling, and other products. Dermatologist increased min dose to 5mg, expecting better results at 6-month mark.

After one month of treatment for hair loss, which included Dutasteride, oral Minoxidil, PRP with Dutasteride mesotherapy, microneedling, supplements, and a shampoo with finasteride and minoxidil, the user observed thicker hair and signs of new hair growth with no bad side effects. They plan to provide another update at the three-month mark.

The effectiveness of pyrilutamide, a hair loss treatment, with research results being postponed until September. Various people shared their experiences with topical finasteride, minoxidil and RU58841, as well as other treatments such as dandruff shampoo, group buys and grey markets.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.